Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment

Area of Science:

• Molecular Biology
• Cancer Genetics
• Signal Transduction

Background:

• The PI3K regulatory subunit p85α (PIK3R1) is essential for inhibiting the PI3K p110 catalytic subunit.
• PIK3R1 mutations can lead to altered PI3K signaling, impacting cellular functions and potentially driving oncogenesis.

Purpose of the Study:

• To functionally characterize the diverse spectrum of PIK3R1 driver mutations.
• To elucidate the consequences of these mutations on PI3K pathway regulation, including interactions with PTEN.
• To identify therapeutic liabilities associated with different PIK3R1 mutation types for targeted cancer treatment.

Main Methods:

• Functional characterization of PIK3R1 mutations.
• Analysis of PI3K/PTEN signaling pathway alterations.
• Assessment of neomorphic signaling pathway activation.

Main Results:

• Identified PIK3R1 hypomorphs with reduced p110 inhibition.
• Discovered hypomorphs and dominant-negative mutants disrupting p85α regulation of PTEN.
• Observed neomorphic mutants activating novel signaling pathways, leading to diverse tumor phenotypes.

Conclusions:

• PIK3R1 mutations exhibit a wide range of functional consequences, from impaired inhibition to novel pathway activation.
• The diverse phenotypic spectrum necessitates tailored therapeutic strategies for tumors with specific PIK3R1 driver mutations.
• Understanding these functional impacts is key to addressing therapeutic vulnerabilities in PIK3R1-mutated cancers.